newsfilter
← Latest News
GlobeNewswire·

First Wave BioPharma Changes Name to Entero Therapeutics

Rebranding introduced as Company advances toward Phase 3 clinical trial with lead asset – latiglutenase for the treatment of celiac disease New Nasdaq ticker symbol is "ENTO" effective May 17, 2024 BOCA RATON, Fla.,